Format

Send to

Choose Destination
See comment in PubMed Commons below
Macromol Biosci. 2013 Apr;13(4):464-9. doi: 10.1002/mabi.201200384. Epub 2013 Jan 11.

An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.

Author information

1
Department of Bioengineering, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado 80045, USA.

Abstract

Reverse thermal gels have numerous biomedical implications, as they undergo physical gelation upon temperature increases and can incorporate biomolecules to promote tissue repair. Such a material is developed for the sustained release of bevacizumab (Avastin), a drug used to treat age-related macular degeneration. The polymer, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU), forms a physical gel when heated to 37 °C and shows good cytocompatibility with ocular cells. ESHU is capable of sustaining bevacizumab release over 17 weeks in vitro, and the release kinetics can be altered by changing the drug dose and the ESHU concentration. These results suggest that ESHU is biologically safe, and suitable for ocular drug delivery.

PMID:
23316011
PMCID:
PMC4142681
DOI:
10.1002/mabi.201200384
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center